RIPK1 and cancer: In the context of cancer, SPOP/RIPK1/RIPK3 axis is dysregulated across multiple cancer types, and the combination of the Smac mimetic SM164 enhances the antitumor efficacy of sunitinib in tumors with high expression of SPOP/RIPK1.